Previous 10 | Next 10 |
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will rep...
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster prese...
HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointmen...
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company m...
2023-03-07 10:35:21 ET Alaunos Therapeutics, Inc. (TCRT) Q4 2022 Earnings Conference Call March 7, 2023 08:30 AM ET Company Participants Danielle Dudgeon - Stern IR Kevin Boyle Senior - CEO Drew Deniger - VP, Research and Development Abhi Srivastava - VP, Tec...
2023-03-07 07:03:53 ET Alaunos Therapeutics press release ( NASDAQ: TCRT ): Q4 GAAP EPS of -$0.04 beats by $0.03 . As of December 31, 2022, Alaunos had approximately $53.0 million in cash balances, which includes restricted cash of approximately $13.9 million. Base...
Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T efforts Advancing TCR-T Library Program towards Phase 2 readiness with accelerated patient enr...
2023-03-06 11:10:18 ET Alaunos Therapeutics ( NASDAQ: TCRT ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, before markets open. The consensus EPS Estimate is -$0.07 (-40.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 1 year, TCRT ...
2023-03-06 10:17:11 ET Major earning expected before the bell on Tuesday include: Canaan ( CAN ) DICK'S Sporting Goods ( DKS ) Sea ( SE ) Alaunos Therapeutics ( TCRT ) Thor Industries ( THO ) For further details see: Notable earnings befor...
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended D...
News, Short Squeeze, Breakout and More Instantly...
Alaunos Therapeutics Inc. Company Name:
TCRT Stock Symbol:
NASDAQ Market:
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...